Dr. Kazmi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5323 Harry Hines Boulevard
Dallas, TX 75390Phone+1 214-645-4673Fax+1 214-645-2542
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013- University of Texas Health Science Center at HoustonResidency, Internal Medicine, 2007 - 2010
Aga Khan Medical CollegeClass of 2004
Certifications & Licensure
TX State Medical License 2017 - 2026
NM State Medical License 2013 - 2019- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib Start of enrollment: 2017 Jun 07
- Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study Start of enrollment: 2019 Nov 22
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 14 citationsA Propensity Score Analysis of Chemotherapy Use in Patients With Resectable Gallbladder Cancer.Muhammet Ozer, Nina N Sanford, Matthew Porembka, Hajra Khurshid, Chul Ahn
JAMA Network Open. 2022-02-01 - 194 citationsCharacterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatmentMaria Pia Morelli, Michael J. Overman, Arvind Dasari, Syed Mohammad Ali Kazmi, Thibault Mazard
Annals of Oncology. 2015-01-26 - 22 citationsVEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment.Yuqing Zhang, Huocong Huang, Morgan Coleman, Arturas Ziemys, Purva Gopal
JCI Insight. 2021-10-21
Press Mentions
jb1-802 by JubilantSeptember 30th, 2021- Jubilant Therapeutics Strengthens Board of Directors with Addition of Leila Alland, M.D. And Announces Appointment of Jeremy Barton, M.D., as Strategic Advisor and Interim CMOAugust 16th, 2021
- Jubilant Therapeutics Announces Appointment of Luca Rastelli, Ph.D. As Chief Scientific OfficerMarch 8th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
